Copyright
©2014 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Feb 6, 2014; 5(1): 40-49
Published online Feb 6, 2014. doi: 10.4292/wjgpt.v5.i1.40
Published online Feb 6, 2014. doi: 10.4292/wjgpt.v5.i1.40
Table 2 Characteristics of trials included in Rothwell et al study and details of post-trial follow-up
| Thromobosis prevention trial | Swedish aspirin low dose trial | UK-TIA aspirin trial | British doctors aspirin trial | |
| ASA comparison | 75 mg/d vs placebo | 75 mg/d vs placebo | 300 mg vs 1200 mg/d vs placebo | 500 mg/d vs placebo |
| Recruitment period | 1989-1992 | 1984-1989 | 1979-1985 | 1978-7199 |
| Median duration of scheduled treatment in original trial (yr) | 6.9 | 2.7 | 4.4 | 6 |
| Year post-trial follow up extended to | 2009 | 2007 | 2006 | 2002 |
- Citation: Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 2014; 5(1): 40-49
- URL: https://www.wjgnet.com/2150-5349/full/v5/i1/40.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v5.i1.40